Search hospitals

>

Iowa

>

Council Bluffs

Jennie Edmundson Memorial Hospital

Claim this profile

Council Bluffs, Iowa 51503

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Pancreatic Cancer

Conducts research for Breast Cancer

33 reported clinical trials

7 medical researchers

Photo of Jennie Edmundson Memorial Hospital in Council BluffsPhoto of Jennie Edmundson Memorial Hospital in Council Bluffs

Summary

Jennie Edmundson Memorial Hospital is a medical facility located in Council Bluffs, Iowa. This center is recognized for care of Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer and other specialties. Jennie Edmundson Memorial Hospital is involved with conducting 33 clinical trials across 136 conditions. There are 7 research doctors associated with this hospital, such as Ralph Hauke, MD, Timothy Huyck, Robert M. Langdon, and Kirsten M. Leu.

Area of expertise

1

Lung Cancer

Global Leader

Jennie Edmundson Memorial Hospital has run 12 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Cancer

Jennie Edmundson Memorial Hospital has run 10 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HPV negative

Top PIs

Clinical Trials running at Jennie Edmundson Memorial Hospital

Skin Cancer

Ovarian Cancer

Lung Cancer

Laryngeal Cancer

Oral Cancers

Oropharyngeal Carcinoma

Non-Small Cell Lung Cancer

Cancer

Throat Cancer

Esophageal cancer

Image of trial facility.

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Gabapentin

for Pain in Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region

Recruiting

1 award

Phase 3

14 criteria

Image of trial facility.

Data Repository

for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Recruiting

1 award

N/A

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Jennie Edmundson Memorial Hospital?